25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察

目的 研究25+微创玻璃体视网膜手术(VRS)联合玻璃体腔注射雷珠单抗(IVR)治疗增生型糖尿病视网膜病变(PDR)的效果。 方法 选取行25+微创VRS患者88例(88眼),分为治疗组(n=44)和对照组(n=44)。治疗组术前3~5 d予以IVR治疗后行25+微创VRS;对照组仅行25+微创VRS。比较两组患者术中情况、最佳矫正视力(BCVA)、眼压及术后并发症情况。 结果 治疗组患者的手术时间、电凝次数、医源性裂孔发生率、玻璃体腔硅油填充率均低于对照组(P<0.05);术后两组患者BCVA均高于术前(P<0.05),术后两组患者眼压均低于术前(P<0.05);术后3个月,治疗组患者玻璃体积血发生率、牵拉性视网膜脱离发生率均低于对照组(P<0.05)。 结论 行25+微创VRS联合IVR可有效缩短手术时间,降低医源性裂孔和玻璃体出血发生率,降低硅油填充率,有助于PDR患者术后视力的恢复。     

玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察

目的研究玻璃体腔注射雷珠单抗(IVR)治疗有临床意义的黄斑水肿(CSME)及非临床意义的黄斑水肿(NCSME)患者的临床效果。方法将糖尿病黄斑水肿(DME)的患者77例,分为CSME组及NCSME组,行IVR治疗,比较治疗前后患者的最佳矫正视力(BCVA)和黄斑水肿最高高度。结果两组治疗1个月后,BCVA较治疗前差异均有统计学意义(P0.05)。两组间比较,治疗前后各时间点黄斑水肿最高高度差异均无统计学意义(P0.05)。结论 CSME及NCSME患者行IVR治疗后黄斑水肿高度降低,但黄斑水肿高度不能完全反映患者视力情况。     

玻璃体腔注射雷珠单抗联合FP-7Ahmed青光眼引流阀植入术治疗新生血管性青光眼的疗效观察

目的探讨玻璃体腔注射雷珠单抗联合FP-7Ahmed青光眼引流阀植入术治疗新生血管性青光眼（NVG）的疗效。方法选取采用玻璃体腔注射雷珠单抗联合FP-7Ahmed青光眼引流阀植入术治疗的NVG患者36例（38眼）作为观察组,选取同期仅给予FP-7Ahmed青光眼引流阀植入术治疗的NVG患者34例（35眼）作为对照组。比较两组患者虹膜表面新生血管消退情况、眼压、视力及并发症发生率。结果观察组35眼（92.1%）虹膜表面新生血管完全消退,3眼（7.9%）残存少许新生血管,对照组所有患者虹膜表面仍可见新生血管。观察组术后1d、7d、1个月、3个月和6个月眼压均显著低于对照组（均P＜0.05）。观察组术后6个月视力较对照组显著改善（P＜0.05）。两组患者角膜水肿、前房渗出、浅前房和低眼压发生率比较差异均无统计学意义（均P＞0.05）。观察组前房出血和引流管堵塞发生率均显著低于对照组（均P＜0.05）。结论玻璃体腔注射雷珠单抗联合FP-7Ahmed青光眼引流阀植入术治疗NVG安全有效。     

雷珠单抗联合光动力疗法治疗湿性年龄相关性 黄斑变性的黄斑形态学变化分析

目的 分析雷珠单抗联合光动力疗法（PDT）治疗湿性年龄相关性黄斑变性的黄斑形态学变化。方 法 收集湿性年龄相关性黄斑变性患者57 例（1 眼/ 例）并分为观察组30 例（雷珠单抗联合光动力疗法）和对 照组27 例（雷珠单抗单药治疗）。比较两组治疗后黄斑形态学的变化。结果 治疗后黄斑中心凹厚度（CMT） 及病变面积均呈下降趋势（P <0.05）,观察组下降幅度高于对照组。治疗后1 个月下降幅度最大,观察组和对照 组CMT 下降幅度分别为（87.5±12.8）和（60.1±16.6）μm ;观察组和对照组黄斑病变面积减少幅度分别 为（2.5±0.6）和（1.8±0.7）mm2。治疗后12 个月观察组和对照组黄斑病变面积减少有效率分别为93.3% 和 77.8%。结论 与单药治疗相比,雷珠单抗联合光动力疗法更能提高黄斑形态学改善的效果。     

Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD

Purpose To report a case of retinal pigment epithelial tear following intravitreal ranibizumab injection for subfoveal choroidal neovascularization. Methods Retrospective single case review. Results A 78-year-old Caucasian female was treated with intravitreal ranibizumab for occult subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD). She returned for evaluation with decreased vision and was found to have a retinal pigment epithelial tear on biomicroscopy. Fluorescein angiography and OCT testing confirmed the clinical findings. Conclusion Although a pigment epithelial tear in neovascular AMD can represent natural history, prior reports of such tears after thermal laser, photodynamic therapy with verteporfin and following intravitreal injection of pegaptanib Na combined with this case report suggest that clinicians should be aware of and monitor patients for the possibility of this complication after intravitreal injections of ranibizumab.     

雷珠单抗联合577nm微脉冲激光治疗重度糖尿病性黄斑水肿

目的:观察雷珠单抗联合577nm微脉冲激光治疗重度糖尿病性黄斑水肿(DME)的临床疗效。方法:选取2016-06/2019-09就诊于广西壮族自治区人民医院确诊为重度DME的患者52例52眼,随机分为观察组(26例26眼,予雷珠单抗联合577nm微脉冲激光治疗)和对照组(26例26眼,仅予雷珠单抗治疗)。两组患者均予“3+PRN”方案行玻璃体腔注射雷珠单抗治疗。治疗(首次玻璃体腔注射)后随访9mo,观察黄斑中心凹厚度(CMT)、最佳矫正视力(BCVA)情况及玻璃体腔注射雷珠单抗次数。结果:与治疗前相比,两组患者治疗后各时间点CMT、BCVA均明显改善(均P<0.001),但两组间均无差异(P>0.05)。随访期间,观察组玻璃体腔雷珠单抗注射次数明显少于对照组(5.88±1.24次vs 7.12±1.24次,P=0.001)。结论:雷珠单抗联合577nm微脉冲激光和单用雷珠单抗均能有效降低重度DME患者黄斑水肿程度,改善视力,但联合治疗可减少雷珠单抗的注射次数。     

Functional and morphological changes in diabetic macular edema over the course of anti‐vascular endothelial growth factor treatment

Purpose:  To evaluate macular morphology and function in diabetic macular edema (DME) over the course of intravitreal anti‐vascular endothelial growth factor (VEGF) treatment with Ranibizumab. Methods:  A consecutive series of 39 study eyes with centre‐involving DME were included in this study. In all subjects, best‐corrected visual acuity (BCVA) according ETDRS protocol, fluorescein angiography (FA), microperimetric macular sensitivity (MP) and Spectral Domain optical coherence tomography (SD‐OCT) cross‐sectional scans were obtained before treatment and after 3 monthly applied intravitreal Ranibizumab injections. Six different morphological qualities [IS/OS layer integrity, outer nuclear layer (ONL) cysts, ONL cyst size, inner nuclear layer (INL) cysts, blocking phenomenon and subretinal fluid] were graded of each cross‐sectional OCT scan before and over the course of treatment by two experienced graders. Correlation analyses between functional and morphological parameters were obtained. Results:  Mean BCVA increased from 26 ± 14 to 33 ± 13 letters after 3 consecutive monthly applied Ranibizumab injections (p < 0.001). Central retinal thickness (CRT) decreased from 504 ± 144 to 387 ± 122 μm (p < 0.001). Over the course of treatment, IS/OS continuity improved (index: 0.56 ± 0.52 to 0.43 ± 0.49, Z = ?1.415, p = 0.157), ONL cyst prevalence and size decreased significantly (index: 0.61 ± 0.44 to 0.56 ± 0.35, Z = ?3.41, p = 0.001 and 1.75 ± 0.88 to 1.17 ± 1.05, Z = ?4.02, p < 0.001), INL cyst prevalence decreased (index: 0.35 ± 0.52 to 0.28 ± 0.52, Z = ?1.60, p = 0.109), blocking phenomenon did not change significantly (index: 00.12 ± 0.16 to 0.13 ± 0.15, Z = ?0.45, p = 0.656) and subretinal fluid almost disappeared (index: 0.10 ± 0.24 vs. 0.00 ± 0.01, Z = ?2.56, p = 0.011). Correlation analyses revealed highest significant correlations between ONL cyst prevalence and their size and CRT as well as BCVA and MP before treatment and over the course of treatment. Conclusions:  ONL cysts and their size as morphological parameters correlate with retinal function measured with BCVA and microperimetry before and over the course of anti‐VEGF therapy with Ranibizumab in patients with DME.     

抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性的一年疗效观察

目的 观察连续12个月玻璃体腔注射抗血管内皮生长因子单克隆抗体ranibizumab(商品名Lucentis)治疗渗出型老年性黄斑变性(AMD)的临床疗效和安全性.方法 前瞻、无对照、开放性研究.经荧光素眼底血管造影(FFA)和吲哚青绿血管造影(ICGA)检查确诊的22例渗出型AMD患者22只眼纳入研究.患者中,男性18例,女性4例;年龄46～79岁,平均年龄(68.2±9.3)岁.采用国际标准视力表行最佳矫正视力(BCVA)和光相干断层扫描(OCT)检查,非接触眼压计测量眼压.为便于统计分析,视力换算为最小分辨角对数视力(logMAR).患眼BCVA 0.01～0.9,平均BCVA 0.26±0.22,平均logMAR0.76±0.44;黄斑中心视网膜厚度(CRT) 182～559 μm,平均CRT值为(302.62±90.18)μm.眼压均正常.玻璃体腔注射10 mg/ml的ranibizumab 0.05 ml(含ranibizumab 0.5 mg),每一个月1次,连续12个月.每次治疗后1h和治疗后1d行眼压检查.每一个月均采用首次治疗前的方法和设备行视力、眼压、眼底、OCT检查;3个月行FFA、ICGA检查.22例患者中,完成了12个月随访者13例.13例患者平均logMAR 0.74±0.37,平均CRT值为(305.77±99.69) μm,平均眼压为(12.07±3.93) mm Hg(1 mm Hg=0.133 kPa).采用配对t检验对比分析治疗过程中视力、CRT变化.结果 所有患眼治疗后1个月,平均logMAR为0.52±0.32,与首次治疗前平均logMAR比较,差异有统计学意义(t=4.518,P＜0.05);治疗后3个月,平均logMAR为0.37±0.27,与首次治疗前比较,差异有统计学意义(t=6.237,P＜0.05).完成12个月随访的13只眼,治疗后1、3、12个月平均logMAR分别为0.51±0.34、0.35±0.26、0.34±0.30,与首次治疗前平均logMAR比较,差异均有统计学意义(t=3.443,5.438,4.756;P＜0.05).治疗后1、3个月平均CRT值分别为(228.85±54.93)、(231.00±38.94) μm,与首次治疗前平均CRT值比较,差异有统计学意义(t=2.914,3.199;P＜0.05);治疗后12个月平均CRT值为(262.92±70.48)μm,与首次治疗前平均CRT值比较,差异无统计学意义(t=1.408,P＞0.05).前3次治疗视力提高最快,6只眼视力从0.1～＜0.5提高到0.5及以上;随访第1个月时CRT降低幅度最大.玻璃体注射ranibizumab后1h眼压升高,1d后降至治疗前水平.随访中未见眼内感染等与玻璃体腔注射相关的并发症.结论 每一个月玻璃体腔注射1次ranibizumab可以提高患眼视力,减轻黄斑水肿;无与治疗相关的不良反应发生.     

雷珠单抗临床应用新进展概述

雷珠单抗(ranibizumab)是第二代人源化抗血管内皮生长因子(VEGF)重组鼠单克隆抗体片段,能与所有活性形式的VEGF-A结合,防止其与VEGFR1及VEGFR2结合,从而减少血管内皮细胞增殖和降低血管通透性,抑制新生血管生成。近年来,其临床应用范围不断扩大,新的观察结果和观点、理念不断涌现。现将近年来雷珠单抗在眼科临床应用的最新进展作一综述。